Efficacy and safety of a novel treatment scheme of RC48-ADC plus PD-1 inhibitors in metastatic urothelial carcinoma: a multicenter real-world study.

Ther Adv Med Oncol · 2025 · PMC12665017 · PMID 41328443

Europe PMC DOI

hedged sentences

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

did not reach statistical significancep = 0.08so close (0.05 < p ≤ 0.1)

Additionally, the mPFS was longer in patients with normal renal function than in those with renal impairment (12.3 vs 8.1 months), though the difference did not reach statistical significance ( p = 0.08).

also in 75,868 other papers

a favorable trendno p-value reported

45 , 46 Our study results showed that while outcomes of concurrent chemoradiotherapy were comparable to systemic treatment alone (ORR: 78% vs 69%, mPFS: 13.4 vs 9.2 months), the concurrent radiotherapy group demonstrated a favorable trend in hazard ratio (HR = 1.78, 95% CI: 0.70–4.54) suggesting better prognosis, though the difference did not reach statistical significance ( p = 0.23).

also in 1,005 other papers

an increasing trendno p-value reported

In terms of safety, the incidence of TRAEs in patients with renal impairment showed an increasing trend as renal function worsened, but no grade 4–5 adverse events were observed.

also in 38,133 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.